Novo’s semaglutide shows obesity benefit in Phase II trial

Data from a Phase II study to treat obesity showed subcutaneous semaglutide (NN9535) from Novo Nordisk A/S (CSE:NOVOB; NYSE:NVO) led to an estimated weight loss benefit of up to 13.8% vs. 2.3% for placebo, combined with diet and exercise. Next year, Novo plans to start Phase III testing of the candidate for the weight loss indication.

The figures correspond to a loss of up to 17.8 kg from a mean baseline weight of 111 kg and a body mass index of about 39 kg/m2 in the semaglutide group. The company said semaglutide was well tolerated, and gastrointestinal side effects were the most common adverse events...